Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
Patients with diabetes mellitus (DM) have an increased risk of adverse atherothrombotic
events. This may be in part attributed to the fact that these patients have reduced response
to oral antiplatelet medications, in particular the P2Y12 receptor inhibitor clopidogrel,
used for secondary prevention of ischemic events. Prasugrel and ticagrelor are recently
approved P2Y12 receptor inhibitors which, compared with clopidogrel, have more potent
antiplatelet effects. Head-to-head comparisons between the two drugs are lacking.